Breast Patents (Class 514/19.4)
-
Publication number: 20120276126Abstract: The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.Type: ApplicationFiled: July 11, 2012Publication date: November 1, 2012Applicant: AGENNIX AGInventors: Atul Varadhachary, Rick Barsky, Federica Pericle, Karel Petrak, Yenyun Wang
-
Publication number: 20120276082Abstract: The present invention relates to agents for use in treating cancer. The agent to be used is an antagonist of Dsg2, wherein said antagonist modulates the function of the amino acid sequence: TQDVFVGSVEELSAAHTLVMKINATDADEPNTLNSKISYR (SEQ ID NO:1), or a fragment or variant thereof, of the EC2 domain of Dsg2. Also included in the invention are specific polypeptides and pharmaceutical preparations. Also included in the invention is a method of screening for antagonists of Dsg2, wherein said antagonist modulates the function of the amino acid sequence: TQDVFVGS VEELSAAHTLVMKINATDADEPNTLNSKISYR (SEQ ID NO: 1), or a fragment or variant thereof, of the EC2 domain of Dsg2.Type: ApplicationFiled: September 22, 2010Publication date: November 1, 2012Applicant: ASCLEPIUMM LIMITEDInventor: Min-Che Chen
-
Publication number: 20120270800Abstract: The invention relates to bifunctional stapled or stiched peptides comprising a targeting domain, a linker moiety, and an effector domain, that can be used to tether, or to bring into close proximity, at least two cellular entities (e.g., proteins). Certain aspects relate to bifunctional stapled or stiched peptides that bind to an effector biomolecule through the effector domain and bind to a target biomolecule through the targeting domain. Polypeptides and/or polypeptide complexes that are tethered by the bifunctional stapled or stiched peptides of the invention, where the effector polypeptide bound to the effector domain of the bifunctional stapled or stiched peptide modifies or alters the target polypeptide bound to the targeting domain of the bifunctional peptide. Uses of the inventive bifunctional stapled or stiched peptides including methods for treatment of disease (e.g., cancer, inflammatory diseases) are also provided.Type: ApplicationFiled: July 13, 2010Publication date: October 25, 2012Applicant: President and Fellows of Harvard CollegeInventors: Gregory L. Verdine, Tom N. Grossmann, Raymond E. Moellering, Tsung-Han Johannes Yeh, Yue Liang, Youbean Oak
-
Publication number: 20120270801Abstract: The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX2X3X4A X6X7EIW X11LPNL X16X17X18QX20 X21AFIX25 X26LX28D, and ii) an N amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.Type: ApplicationFiled: October 27, 2010Publication date: October 25, 2012Applicant: AFFIBODY ABInventors: Fredrik Frejd, Elin Gunneriusson, Nina Kronqvist, John Löfblom, Stefan Ståhl
-
Publication number: 20120270769Abstract: The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes and methods of using the compounds. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the same. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections.Type: ApplicationFiled: October 22, 2010Publication date: October 25, 2012Inventors: Éric Marsault, Olivier Leogane, Axel Mathieu, Sylvie Beaubien, Richard Leduc
-
Publication number: 20120270799Abstract: The invention relates to methods of identifying a candidate compound which may inhibit estrogen receptor-dependent transcription or ?9-nAChR overexpression and proliferation of nicotine-derived-compound-induced breast cancer cells by using an activating protein 1 (AP1) polypeptide. The invention found that ?9-nAChR has an activating protein 1 (AP1)-binding site, that the ?9-nAChR promoter is located at the AP1-binding site, and that ERs specifically bind to the ?9-nAChR promoter at the AP1-binding site, indicating that ER-induced ?9-nAChR up-regulation plays a central role in the response to endogenous (E2) or exogenous (nicotine) stimulation.Type: ApplicationFiled: April 21, 2011Publication date: October 25, 2012Applicant: TAIPEI MEDICAL UNIVERSITYInventors: Chia-Hwa Lee, Ya-Chieh Chang, Ching-Shyang Chen, Shih-Hsin Tu, Ying-Jan Wang, Li-Ching Chen, Yu-Jia Chang, Po-Li Wei, Hui-Wen Chang, Chien-Hsi Chang, Ching-Shui Huang, Chih-Hsiung Wu, Yuan-Soon Ho
-
Publication number: 20120263685Abstract: The present invention relates to a composition for preventing or treating cancer, which contains one or more selected from the group consisting of human adult stem cells and their secretory products, and to a method of preventing or treating cancer using the same. Particularly, the invention relates to the use of adult stem cells that exhibit the effect of preventing or treating cancer by activating the immune system. The human adult stem cells of the invention are administered by a simple method such as intravenous injection and are highly valuable as a cell therapeutic agent for treating various cancer (tumor) diseases. Thus, the adult stem cells will be highly useful in anticancer studies.Type: ApplicationFiled: April 7, 2010Publication date: October 18, 2012Applicant: RNL BIO CO., LTDInventors: Jeong Chan RA, Sung Keun KANG, Sang Kyu WOO, Hwa Young YOUN, Hee Woo LEE, Kyoung Won SEO
-
Publication number: 20120258099Abstract: A peptide including the amino acids sequence X9CGYX13X14AX16X17X18MX20X21X22X23X24X25X26X27CPLCX32X33, a nucleic acid coding for the peptide, and/or a recombinant vector including the nucleic acid for the preparation of a drug intended for the treatment of cancer.Type: ApplicationFiled: October 22, 2009Publication date: October 11, 2012Applicants: UNIVERSITE MONTPELLIER 2 - SCIENCES ET TECHNIQUES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Anne Debant, Susanne Schmidt, Nathalie Bouquier, Sylvie Fromont
-
Publication number: 20120251538Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.Type: ApplicationFiled: November 12, 2010Publication date: October 4, 2012Applicant: Five Prime Pharmaceutials, Inc.Inventors: Thomas Harding, Michael W. Kavanaugh
-
Patent number: 8278278Abstract: Cell-permeable caPCNA-derived peptides and their variants serve as therapeutic compositions to reduce the proliferation of cancerous cells and also augment cytotoxic effects of chemotherapeutics.Type: GrantFiled: October 7, 2010Date of Patent: October 2, 2012Assignee: Indiana University Research and Technology CorporationInventors: Linda H. Malkas, Robert J. Hickey
-
Publication number: 20120244163Abstract: Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.Type: ApplicationFiled: April 10, 2012Publication date: September 27, 2012Applicants: DYAX CORP., MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Arthur J. KUDLA, Arumugam MURUGANANDAM, David BUCKLER, Alexey Alexandrovich LUGOVSKOY, Jonathan Basil FITZGERALD, Lihui XU, Neeraj KOHLI
-
Patent number: 8273705Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with Bcl-2-family members.Type: GrantFiled: February 2, 2009Date of Patent: September 25, 2012Assignee: The Burnham InstituteInventors: John C. Reed, Xiao-kun Zhang, Bin Guo, Bingzhen Lin, Siva Kumar Kolluri
-
Publication number: 20120237614Abstract: The present invention concerns a SIMP peptide (Short-interfering mutant p53 peptides) suitable to disrupt the protein complexes within tumour cells resulting from m-p53 and p73 proteins selectively in tumours wherein m-p53 contains His273 mutation.Type: ApplicationFiled: May 6, 2010Publication date: September 20, 2012Inventors: Gennaro Citro, Giovanni Blandino, Sabrina Strano, Silvia Di Agostino
-
Publication number: 20120237552Abstract: Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK/JNK phosphorylation to various extents in both cell lines.Type: ApplicationFiled: August 31, 2010Publication date: September 20, 2012Inventors: Beatriz Moreno, Pablo Villoslada, Joaquin Messeguer, Gloria Navarro, Angel Messeguer
-
Publication number: 20120225825Abstract: Methods and compositions relating to CDP-taxane conjugates are described herein.Type: ApplicationFiled: April 6, 2012Publication date: September 6, 2012Applicant: CERULEAN PHARMA INC.Inventors: Thomas C. Crawford, Oliver S. Fetzer, Lawrence Alan Reiter, Marc Wolfgang
-
Patent number: 8258100Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: June 19, 2009Date of Patent: September 4, 2012Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Patent number: 8258098Abstract: The present invention relates to combinations of aplidine or aplidine analogues with other titumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.Type: GrantFiled: February 28, 2007Date of Patent: September 4, 2012Assignee: Pharma Mar, S.A.Inventors: Glynn Thomas Faircloth, Pablo Manuel Aviles Marin, Doreen LePage, Jesus San Miguel Izquierdo, Atanasio Pandiella
-
Publication number: 20120220539Abstract: The present invention relates conotoxin peptides that are analogs of the ?-contoxin peptide RgIA. These conotoxin peptides block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, such as neuropathic pain and inflammatory pain, inflammatory disorders, such as rheumatic diseases, and in the treatment of breast cancer.Type: ApplicationFiled: November 4, 2011Publication date: August 30, 2012Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: J. Michael MCINTOSH, Baldomero M. OLIVERA, Michael ELLISON, Michelle A. VINCLER
-
Publication number: 20120220540Abstract: The present application provides synbodies against AKT1 differing in amino acid sequence, conjugation chemistry, linker/scaffold, or adjunct moiety. The synbodies are useful for diagnosis and treatment of cancer and as research reagents.Type: ApplicationFiled: March 1, 2012Publication date: August 30, 2012Applicant: ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITYInventors: Stephen A. Johnston, Christopher Diehnelt, Nidhi Gupta, Paul Belcher
-
Patent number: 8252740Abstract: Elastin-like polypeptide (ELP) serves as a vector for thermally-targeted delivery of therapeutics, including cytotoxic chemotherapeutic drugs such as doxorubicin. Examples of an ELP-based delivery vehicle can comprise: (1) a cell penetrating peptide, such as a Tat peptide, (2) ELP, and (3) the lysosomally degradable glycylphenylalanylleucylglycine (GFLG) (SEQ ID NO: 3) spacer and a cysteine residue (SEQ ID NO: 4) conjugated to therapeutic such as doxorubicin, or an analog thereof.Type: GrantFiled: January 29, 2007Date of Patent: August 28, 2012Assignee: The University of Mississippi Medical CenterInventors: Drazen Raucher, Gene Bidwell, III, Waldemar Priebe, Izabela Fokt
-
Publication number: 20120214744Abstract: The present invention relates to polypeptides, nucleic acids and pharmaceutical compositions suitable for use in the treatment of ErbB2 dependent-cancers, in particular of tumors overexpressing ErbB2 or expressing mutated forms of the ErbB2 gene.Type: ApplicationFiled: September 23, 2010Publication date: August 23, 2012Inventors: Sandrine Bourdoulous, Rym Djerbi-Bouillie
-
Publication number: 20120213736Abstract: According to the invention, parvoviruses such as the adeno-associated virus Type 2 (AAV2) are found to be oncolytic, selectively mediating apoptosis in cancer cells and their precursors, while leaving healthy cells intact. The invention also includes a method of killing cancer and other neoplastic and preneoplastic cells by administrating to said cells the AAV2 proteins Rep78 or Rep 68, expression constucts encoding the same, or pharmaceutical compositions comprising the same.Type: ApplicationFiled: December 13, 2011Publication date: August 23, 2012Applicant: THE PENN STATE RESEARCH FOUNDATIONInventors: Craig M. Meyers, Samina Alam
-
Patent number: 8247372Abstract: Compounds which are Spiruchostatin analogues of the general formula (I) or (I?), isosteres thereof and pharmaceutically acceptable salts thereof are found to inhibit HDAC wherein R1, R2, R3 and R4 are the same or different and represent an amino acid side chain moiety and each R6 is the same or different and represents hydrogen or C1-C4 alkyl.Type: GrantFiled: November 23, 2007Date of Patent: August 21, 2012Assignee: University of SouthamptonInventors: Graham Keith Packham, Arasu Ganesan, Alexander Richard Liam Cecil
-
Publication number: 20120208770Abstract: A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.Type: ApplicationFiled: February 9, 2012Publication date: August 16, 2012Inventors: Shulin Li, Jeffry Cutrera, Xueqing Xia
-
Publication number: 20120207763Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.Type: ApplicationFiled: April 20, 2012Publication date: August 16, 2012Applicants: ASTEX THERAPEUTICS LIMITED, NOVARTIS AGInventors: Christopher Thomas BRAIN, Moo Je SUNG, Gebhard THOMA
-
Publication number: 20120208769Abstract: The present invention relates to chemokine-mucin fusions linked to glycosylphosphatidylinositol (GPI)-anchors and their use as anti-cancer adjuvants and as agents in tissue regeneration and suppression of vascular damage. GPI-linked chemokines are incorporated in the surface membrane of tumour cells and effect a recruitment of cytotoxic immune cells to the tumour site following injection in vivo. Leukocytes, cytotoxic T-cells and NK cells target the chemokine-GPI-anchored tumour cells and modulate cell-mediated lysis of the tumour cells. The efficiency of GPI-anchoring and modulation of immune cells can be further enhanced by linking the chemokine to a mucin domain followed by the GPI-anchor. The GPI-anchored chemokines, with or without mucin domain, are remarkably useful for the inhibition of tumour growth, tissue regeneration, and suppression of acute vascular damage to allografts.Type: ApplicationFiled: November 30, 2006Publication date: August 16, 2012Inventors: Peter Jon Nelson, Ralf Huss, Hermann-Josef Grone
-
Publication number: 20120195916Abstract: A method of treating cancer in a mammal is provided comprising the step of inhibiting TRIM59 expression or activity in the mammal. TRIM59 expression may also be utilized in methods of diagnosing cancer in a mammal.Type: ApplicationFiled: September 10, 2010Publication date: August 2, 2012Inventor: Jian Wu Xuan
-
Publication number: 20120195918Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and others.Type: ApplicationFiled: March 2, 2012Publication date: August 2, 2012Inventor: Haruo Sugiyama
-
Publication number: 20120197059Abstract: The present invention involves the use peptides comprising ubiquitin interacting motifs (UIMs) alone or in combination with other agents to treat diseases involving neovascularization, such as cancer.Type: ApplicationFiled: January 31, 2012Publication date: August 2, 2012Inventors: YUNZHOU DONG, Hong Chen
-
Publication number: 20120195978Abstract: Administration of compositions comprising cell-permeable caPCNA-derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins.Type: ApplicationFiled: October 7, 2010Publication date: August 2, 2012Applicant: Indiana University Research and Technology CorporaInventors: Robert J. Hickey, Linda H. Malkas
-
Publication number: 20120183538Abstract: The invention provides SPARC antisense oligonucleotides and methods of their use in proliferative diseases such as cancer and hepatic fibrosis.Type: ApplicationFiled: July 9, 2010Publication date: July 19, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Vuong Trieu, Larn Hwang, Neil Desai
-
Patent number: 8222214Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: GrantFiled: April 11, 2008Date of Patent: July 17, 2012Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: George E. Peoples, Ponniah Sathibalan
-
Publication number: 20120177610Abstract: Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain GOOD HEALTHY CELLS and the combination of any of these known or unknown proteins which contain any one of these GOOD HEALTHY cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Marcophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.Type: ApplicationFiled: May 24, 2011Publication date: July 12, 2012Inventor: Kieu Hoang
-
Publication number: 20120178699Abstract: Disclosed is the use of a klotho protein or related compounds (especially KL1 or KL1 analogue) for treatment, and especially treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents.Type: ApplicationFiled: March 25, 2012Publication date: July 12, 2012Applicant: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.Inventors: Ido WOLF, Tamar RUBINEK, Bella KAUFMAN, Lilach ABRAMOVITCH
-
Publication number: 20120178697Abstract: The Wnt signaling pathways are involved in embryo development as well as in tumorigenesis. Dishevelled (Dvl) tranduces Wnt signals from the receptor Frizzled (Fz) to downstream components in canonical and non-canonical Wnt signaling pathways, and the Dvl PDZ domain plays an essential role in both pathways, and the Dvl PDZ domain binds directly to Fz receptors. In the present invention using NMR-assisted virtual ligand screening, several compounds were identified and were found to bind to the Dvl PDZ domain. Molecular dynamics simulation was used to analyze the binding between the PDZ domain and these compounds in detail. These compounds provide a basis for rational design of high-affinity inhibitors of the PDZ domain, which can block Wnt signaling by interrupting the Fz-Dvl interaction.Type: ApplicationFiled: April 1, 2005Publication date: July 12, 2012Inventors: Jie Zheng, Jufang Shan, Dianqing Wu
-
Patent number: 8217010Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of a solid cancerous tumor are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery of a chemotherapeutic agent to a solid tumor in mammals, including humans.Type: GrantFiled: February 22, 2006Date of Patent: July 10, 2012Assignee: The Board of Trustees of the University of IllinoisInventor: Anil Gulati
-
Publication number: 20120172310Abstract: The present invention provides materials and methods useful to treat various sGC?1-expressing cancers. Materials include peptides which interfere with sGC?1's pro-survival functions, thereby resulting in apoptosis of sGC?1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.Type: ApplicationFiled: May 28, 2010Publication date: July 5, 2012Applicant: UNIVERSITY OF TOLEDOInventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
-
Publication number: 20120172314Abstract: Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.Type: ApplicationFiled: March 14, 2012Publication date: July 5, 2012Applicants: Tel HaShomer Medical Research Infrastructure and Services Ltd., CEDARS-SINAI MEDICAL CENTERInventors: H. Phillip Koeffler, Ido Wolf, Tamar Rubinek, Bella Kaufman, Lilach Abramovitch
-
Publication number: 20120172313Abstract: The present invention relates to methods for preventing or treating proliferative diseases. In particular, the present invention relates to the use of compositions derived or derivable from plants, such as plant defensins, particularly in methods for the prevention or treatment of proliferative diseases such as cancer. The present invention also relates to associated uses, systems and kits.Type: ApplicationFiled: June 23, 2011Publication date: July 5, 2012Inventors: MARK DARREN HULETT, IVAN KA HO POON, AMY ALEXANDRA BAXTER, MARILYN ANDERSON, FUNG LAY
-
Publication number: 20120172285Abstract: A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic resistance of cancer and other diseases associated with impaired cell death.Type: ApplicationFiled: December 9, 2009Publication date: July 5, 2012Inventors: Loren D. Walensky, Michelle L. Stewart
-
Publication number: 20120165244Abstract: The present invention relates to a method for binding Lewis Y antigen of a subject, comprising administering to the subject an effective amount of N-terminal lectin-like domain of thrombomodulin (TMD1), or its analogues.Type: ApplicationFiled: March 13, 2012Publication date: June 28, 2012Inventors: Hua-Lin Wu, Guey-Yueh Shi
-
Publication number: 20120164074Abstract: The invention relates to methods and compositions for inhibiting metastasis, such as by inhibiting FOXC2 expression or activity. The invention further relates to methods of prognosticating, diagnosing, and assisting in the diagnosis of metastasis in an individual, or of determining the metastatic potential of a tumor. The invention further relates to methods of identifying agents which inhibit metastasis.Type: ApplicationFiled: December 1, 2011Publication date: June 28, 2012Inventors: Sendurai Mani, Jing Yang, Robert A. Weinberg
-
Publication number: 20120165267Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.Type: ApplicationFiled: June 6, 2011Publication date: June 28, 2012Applicant: Genentech, Inc.Inventors: Robert F. Kelley, Sarah Hymowitz, Stephanie Ho Lindstrom
-
Publication number: 20120164065Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.Type: ApplicationFiled: January 11, 2012Publication date: June 28, 2012Inventors: Anthony Manganaro, Karen Rockwell
-
Publication number: 20120141479Abstract: Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.Type: ApplicationFiled: July 23, 2008Publication date: June 7, 2012Inventors: Samir E. Witta, Paul A. Bunn, Harry A. Drabkin, Robert M. Gemmill, Daniel Chan
-
Publication number: 20120142606Abstract: The present invention is directed to peptides having affinity for tumor cells. The peptides are useful in pharmaceutical compositions in particular for the treatment of cancer. Further, the peptides are useful in diagnostic compositions, in particular for the diagnosis and imaging of cancer. The peptides according to the present invention are peptides selected from the group consisting of: Z1-KLAKLAKKLAKLAK-Z2-LTVXPWY-Z3, Z1-KLAKLAKKLAKLAK-Z2-LTVXP-Z3, Z1-KLAKLAKKLAKLAK-Z2-TVXPW-Z3, Z1-KLAKLAKKLAKLAK-Z2-VXPWY-Z3, Z1-KLAKLAKKLA KLAK-Z2-XPWY-Z3, Z1-KLAKLAKKLAKLAK-Z2-LTVXPW-Z3, di-, tri-, or multimers of the above sequences, wherein each Z1, Z2 and Z3 independently of one another represents any amino acid sequence of n amino acids, n varying from 0 to 50 and n being identical or different in Z1, Z2, and Z3, and wherein X represents any amino acid, whereby each of the amino acid residues in the above sequences may be independently in either L-form or D-form.Type: ApplicationFiled: April 1, 2009Publication date: June 7, 2012Inventors: Ingo Schmidt-Wolf, Davorka Messmer
-
Publication number: 20120142585Abstract: This invention provides compounds that are true antagonists of the leptin receptor, in the presence and the absence of native leptin or another leptin receptor binder. These compounds may be used to inhibit leptin receptor activity, promote growth arrest or death of leptin receptor-positive cancer cells, or monitor or detect a leptin receptor-positive cell, in vitro or in vivo. These compounds may also be used to treat a weight-loss nutritional disorder, osteoporosis, rheumatoid arthritis, osteoarthritis, or inflammatory bowel disease. Also included in the invention are methods for detecting leptin receptor-positive cells, for arresting cell growth or killing cancer cells in vivo, for monitoring or detecting a leptin receptor-positive cell in vitro or in vivo, for treating a weight-loss nutritional disorder, for treating osteoporosis, for treating rheumatoid arthritis, for treating osteoarthritis, or for treating inflammatory bowel disease.Type: ApplicationFiled: March 30, 2010Publication date: June 7, 2012Applicant: TEMPLE UNIVERSITY-OF THE C0MMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Laszlo Otvos, Eva Surmacz
-
Publication number: 20120141538Abstract: The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.Type: ApplicationFiled: December 16, 2009Publication date: June 7, 2012Applicant: UNIVERSITE PIERRE ET MARIE CURIE -PARIS VIInventors: Guy Gorochov, Karim Dorgham, Christophe Combadiere, Philippe Deterre
-
Publication number: 20120141499Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.Type: ApplicationFiled: January 12, 2012Publication date: June 7, 2012Inventors: Jonathan Daniel OLINER, Hosung Min
-
Publication number: 20120141416Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.Type: ApplicationFiled: June 30, 2010Publication date: June 7, 2012Applicant: Angiochem Inc.Inventors: Michel Demeule, Christian Che, Carine Thiot